Physician profile
Vesna Solheim
NPI 1528043528
$1,645.44
in general payments reported to CMS, 2019-2025
25 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $67.59 · 2021: $88.58 · 2022: $551 · 2023: $373 · 2024: $139 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.32 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innocoll Pharmaceuticals Limited | $251.31 | 2022 | |
| Abbvie INC. | $218.31 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Sanofi-Aventis U.S. LLC | $141.09 | 2019-2021 | |
| Novo Nordisk INC | $138.90 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $130.32 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $80.53 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $72.84 | 2019-2021 | |
| Corcept Therapeutics | $71.58 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $61.73 | 2022-2025 | Shingrix, Arexvy |
| Amgen INC. | $60.32 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $56.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $52.50 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $43.74 | 2022-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $42.52 | 2022-2023 | Mounjaro |
| Astellas Pharma US INC | $40.75 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $33.46 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.02 | 2022 | |
| Lundbeck LLC | $19.79 | 2023 | Rexulti |
| Irhythm Technologies, INC. | $19.35 | 2023 | Zio Xt Patch |
| Dexcom, INC. | $16.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.09 | 2022 | |
| Currax Pharmaceuticals LLC | $16.05 | 2024 | Contrave |
| Jazz Pharmaceuticals INC. | $15.82 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2021 | |
| Merck Sharp & Dohme LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vesna Solheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.